{
    "clinical_study": {
        "@rank": "80524", 
        "acronym": "TOP-DYSK", 
        "arm_group": [
            {
                "arm_group_label": "Topiramate", 
                "arm_group_type": "Active Comparator", 
                "description": "Topiramate as adjunct to amantadine."
            }, 
            {
                "arm_group_label": "Placebo (sugar pill)", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "The study will involve an eighteen-week, double-blind, placebo-controlled parallel designed\n      comparison between add-on topiramate and add-on placebo to stable treatment with amatadine\n      in the treatment of PD patients who continue to have dyskinesia on amantadine."
        }, 
        "brief_title": "Topiramate as an Adjunct to Amantadine in the Treatment of Dyskinesia in Parkinson's Disease", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Idiopathic Parkinson's Disease", 
            "Drug Induced Dyskinesia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Dyskinesias", 
                "Dyskinesia, Drug-Induced", 
                "Parkinson Disease"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Parkinson's disease patient, defined by UK Brain Bank criteria\n\n          2. Current age between 30-90\n\n          3. Clinically pertinent dyskinesias defined by CGI-s score (see attachment) > 3 (mild)\n             established by clinician's total assessment of patient including objective\n             observation during the screening process. *\n\n          4. Stable doses of all antiparkinsonian medications for at least 4 weeks\n\n          5. Stable treatment with at least 200 mg  amantadine for at least 4 weeks.\n\n          6. Presence of a caregiver willing to participate in the study\n\n          7. In the opinion of the enrolling investigator, the subject will be able to maintain\n             current dosing schedule of antiparkinsonian drugs for the duration of the trial.\n\n          8. Subjects must be free of dementia, depression and psychosis as determined by clinical\n             examination.\n\n          9. The subject must be willing to participate in all study related activities and\n             visits.\n\n        Exclusion criteria:\n\n          1. Any subjects with clinical evidence suggestive of an atypical or secondary form of\n             Parkinson's Disease\n\n          2. Any subject who, in the opinion of the Principal Investigator, has a concomitant\n             medical illness which would preclude them from being treated with amantadine,\n\n          3. Any subject who, in the opinion of the Principal Investigator, will be unable to\n             maintain current stable dosing of their anti-parkinsonian medications for the\n             duration of the trial,\n\n          4. Any subject with evidence for dementia, depression, or psychosis, as determined by\n             clinical examination.\n\n          5. Any subject who has not signed informed consent, or unable or unwilling to\n             participate in all of the study related activities."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "90 Years", 
            "minimum_age": "30 Years"
        }, 
        "enrollment": {
            "#text": "55", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 7, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01789047", 
            "org_study_id": "TOP-DYSK"
        }, 
        "intervention": {
            "arm_group_label": "Topiramate", 
            "description": "Topiramate as adjunct to amantadine", 
            "intervention_name": "Topiramate", 
            "intervention_type": "Drug", 
            "other_name": [
                "Topiramate", 
                "Topomax"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Amantadine", 
                "Topiramate"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Parkinson's disease", 
            "dyskinesia", 
            "Indonesia", 
            "amantadine"
        ], 
        "lastchanged_date": "May 21, 2014", 
        "location": [
            {
                "contact": {
                    "email": "rclarkrn@uab.edu", 
                    "last_name": "Rachel Clark, RN", 
                    "phone": "205-996-2647"
                }, 
                "facility": {
                    "address": {
                        "city": "Birmingham", 
                        "country": "United States", 
                        "state": "Alabama", 
                        "zip": "35233"
                    }, 
                    "name": "University of Alabama"
                }, 
                "investigator": {
                    "last_name": "Anthony P Nicholas, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "crocha1@health.usf.edu", 
                    "last_name": "Claudia Rocha, CCRC", 
                    "phone": "813-396-0757"
                }, 
                "facility": {
                    "address": {
                        "city": "Tampa", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33612"
                    }, 
                    "name": "University of South Florida"
                }, 
                "investigator": {
                    "last_name": "Robert Hauser, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "cgoetz@rush.edu", 
                    "last_name": "Christopher G Goetz, MD", 
                    "phone": "312-563-2900", 
                    "phone_ext": "Press 4"
                }, 
                "contact_backup": {
                    "email": "movement_disorder@rush.edu", 
                    "last_name": "Lucia M Blasucci, RN", 
                    "phone": "312-563-2900", 
                    "phone_ext": "Press 4"
                }, 
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60612"
                    }, 
                    "name": "Rush University Medical Center"
                }, 
                "investigator": {
                    "last_name": "Christopher G Goetz, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "lisa.gauger@duke.edu", 
                    "last_name": "Lisa Gauger", 
                    "phone": "919-668-1538"
                }, 
                "facility": {
                    "address": {
                        "city": "Durham", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27705"
                    }, 
                    "name": "Duke University"
                }, 
                "investigator": {
                    "last_name": "Mark Stacy, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Susan.OConnor2@va.gov", 
                    "last_name": "Susan M O'Connor, RN", 
                    "phone": "503-273-5336"
                }, 
                "facility": {
                    "address": {
                        "city": "Portland", 
                        "country": "United States", 
                        "state": "Oregon", 
                        "zip": "97201"
                    }, 
                    "name": "Oregon Health Sciences University"
                }, 
                "investigator": {
                    "last_name": "Kathy Chung, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Topiramate as an Adjunct to Amantadine in the Treatment of Dyskinesia in Parkinson's Disease", 
        "other_outcome": [
            {
                "description": "This is a 4-part scale that rates both non-motor and motor (including dyskinesia) aspects of Parkinson's disease.  Parts of the scales will be completed by the blinded treating physician while assessing the subject and other parts will be self-completed by the subject", 
                "measure": "Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS)", 
                "safety_issue": "No", 
                "time_frame": "Assessed at baseline, week 6, week 10 and week 14"
            }, 
            {
                "description": "Hoehn & Yahr staging of Parkinson's disease is completed by the blinded treating physician assessing the subject", 
                "measure": "Hoehn & Yahr Staging", 
                "safety_issue": "No", 
                "time_frame": "Assessment completed at baseline, week 6, week 10 and week 14"
            }
        ], 
        "overall_contact": {
            "email": "cgoetz@rush.edu", 
            "last_name": "Christopher G Goetz, MD", 
            "phone": "312-942-8016"
        }, 
        "overall_contact_backup": {
            "email": "gstebbin@rush.edu", 
            "last_name": "Glenn T Stebbins, PhD", 
            "phone": "312-563-3854"
        }, 
        "overall_official": {
            "affiliation": "Rush University Medical Center", 
            "last_name": "Christopher G Goetz, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The Unified Dyskinesia Rating Scale (UDysRS) will be the primary outcome measure for this study.  This choice is based on the outcome of the MJFF-funded Validation of Dyskinesia Rating Scales study.  In this study, the UDysRS was identified as the most sensitive scale to detect change in dyskinesia in an 8-week, double-blind, placebo-controlled trial of amatadine.  The UDysRS utilizes rater information, patient self-report and objective measures of dyskinesia to provide assessments of impairment and disability due to dyskinesia.", 
            "measure": "The Unified Dyskinesia Rating Scale (UDysRS)", 
            "safety_issue": "No", 
            "time_frame": "Baseline, Week 10 and week 14 performed by blinded rater"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01789047"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Rush University Medical Center", 
            "investigator_full_name": "Christopher G. Goetz, MD", 
            "investigator_title": "MD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "Clinical Global Impression - Change score", 
            "safety_issue": "No", 
            "time_frame": "Assessed at Week 10 and 14 by blinded treating physician and subject"
        }, 
        "source": "Rush University Medical Center", 
        "sponsors": {
            "collaborator": {
                "agency": "Michael J. Fox Foundation for Parkinson's Research", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Rush University Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}